Illumina, Inc. (ILMN) Earnings Call Transcript & Summary
October 29, 2026
Earnings Call Speaker Segments
Conor McNamara
executiveGood day, everyone, and thanks for joining Illumina's Q3 2026 earnings call. Today we'll go over the financial results we published following the market close and share some prepared comments before we open things up for your questions. You can find our earnings release in the investor relations portion of illumina.com. With me this afternoon are Jacob Thaysen, our Chief Executive Officer, and Ankur Dhingra, our Chief Financial Officer. Jacob will start us off with a business update, and then Ankur will walk through the financials. As you likely noticed in the press release, we recorded certain tariff refunds during the third quarter, and those had a favorable effect on GAAP and non-GAAP operating income, margins, and EPS, while weighing on revenue. Those refunds weren't included in the guidance we gave previously, so every financial measure we discuss today is on an adjusted non-GAAP basis and leaves out the tariff refund impact. You can find reconciliations to non-GAAP and GAAP in today's release as well as in the supplementary data posted on our website. All revenue figures and revenue growth rates exclude tariff refunds. Organic revenue growth is also adjusted for currency effects and acquisitions, and rest of world organic growth additionally leaves out our Greater China region. This call is being recorded, and a replay will be posted on our website. As a reminder, what we provide and discuss today will include forward-looking statements, among them statements regarding Illumina's future events, product outlook, and financial expectations. Actual results could differ materially. For a better understanding of the risks and uncertainties that might cause actual results to differ, please refer to the documents Illumina files with the SEC, including our most recent Forms 10-Q and 10-K; with that, I'll hand the call over to Jacob.
Jacob Thaysen
executiveThanks, Conor, and good afternoon, everyone. We had an excellent third quarter. Demand for clinical sequencing was strong, and NovaSeq X placements came in higher, and those factors pushed revenue, margin, and EPS past the guidance range we had set. Our strategy is delivering results, and I feel proud of what our team achieved for customers and shareholders. Because we keep executing with discipline and our business has momentum, we can lift our guidance for the fiscal year, and we are still on course to hit our long-range financial targets. Before I get into the specifics of our results, I want to point out a few ways our innovation is assisting customers in answering new questions about biology. At the start of 2026, we launched the Billion Cell Atlas to tackle a major obstacle in bringing AI into biology: functional data sets are scarce. To learn, AI models require vast quantities of data; in biology, such models succeed only when that data is precise, standardized, and reproducible. At scale, these data sets are unavailable. Biology has no equivalent of the internet. Our Billion Cell Atlas was created to help overcome these constraints. The Atlas, now more than halfway finished, is progressing toward a perturbation data set built for AI on an unprecedented scale—one that assists biopharma partners in linking genetic signals to cellular mechanisms, bolstering target validation, deepening disease understanding, and making faster drug discovery possible. Our direct collaboration with biopharma companies means we incorporate what they tell us, so the proprietary data set stays relevant and delivers maximum value for both our partners and Illumina. GSK has just become the newest biopharmaceutical company to join the Billion Cell Atlas consortium, which aims to speed up drug discovery, and other companies that want access to the completed Atlas are showing increasing interest. Our partners have taught us a great deal about constructing these data sets for AI, and we identify several opportunities to tackle further bottlenecks throughout drug discovery and development. We regard this as a substantial long-term opportunity and expect to share more details about our strategy over the next few quarters. At ASHG earlier this month, we combined our assays, sequencing platforms, and software to demonstrate how customers can gain from the Illumina BioInsight ecosystem. The strongest illustrations were provided by customers themselves, who demonstrated how merging genomics, transcriptomics, methylation, and proteomics is enabling them to observe biology previously invisible to them, with efforts covering bulk, single-cell, and spatial methods. What customers find compelling is that we consider their work end to end, simplifying access to every component required for high-quality insights while lowering the overall workflow cost. Turning to analysis, we introduced the BioInsight platform. It consolidates our analysis application, AI models, and curated biological data into a single place, which cuts down on how much customers must assemble and manage separate software tools. Customers can also reach SpliceAI2 through the platform—our new AI model that predicts how genetic changes affect RNA splicing. In rare disease research data sets, it found 17% more disease-relevant splice variants than other splicing models. Our teams keep delivering innovation, and I'm proud of that. We believe the coming era of life sciences innovation will be driven not just by sequencing, but equally by software, AI, and differentiated data that unlock the genome's power. With BioInsight, Illumina is laying the foundation for AI biology, enabling stronger foundational models and virtual cell models that could improve how we understand and predict biology. As we get closer to predicting biology, we see a route to applying those insights to shift healthcare toward a more proactive future — spotting risks sooner, preventing disease where possible, and intervening earlier; now let me go deeper on our financial results, beginning with how we performed in the quarter. Customer demand for the NovaSeq X platform is still at very high levels. During the quarter, we placed more than 80 instruments. That works out to roughly 360 NovaSeq X placements across the last four quarters, exceeding our first year of launch. Greater uptake of sequencing-driven diagnostics, along with tests that require heavier sequencing, is what's driving this demand. After those instruments are installed, they'll generate extra consumables revenue for many years to come. In rest of world sequencing consumables, Q3 end market growth rates were comparable to Q2, with clinical up 14% while research and applied each fell 6%. Looking at rest of world sequencing consumables in 2026, our expectation remains mid-teens growth in clinical and mid to high single-digit declines in research and applied. I'll now turn to our outlook for the balance of the year. We're lifting our revenue guidance for the full year, reflecting how Q3 beat our expectations and a stronger Q4, which comes from higher sequencing consumable revenue on a bigger installed base of NovaSeq X. We're also raising our outlooks for full-year margin and EPS, and we now anticipate operating margins of roughly 25% in the second half of 2026, which is about 400 basis points higher than 2024. I'm incredibly proud of the way our teams have handled investments through a difficult environment. With every quarter that goes by, it's clearer that our strategy is paying off. We're delivering what we set out to accomplish in 2024 and seizing emerging opportunities to fuel growth in the years ahead. I'd like to express appreciation to our employees for their dedication and effort on behalf of Illumina, and to our customers for the confidence they show in us. It's my intention to present our 2027 guidance when we hold the fourth quarter earnings call. With that said, I'll hand things over to Ankur, who will review our results and the revised outlook.
Ankur Dhingra
executiveThanks, Jacob, and good afternoon, everyone. I'll go through the financial results for our third quarter, give you some extra detail on revenue, earnings, and cash flow, and then talk about our updated outlook. As Conor said earlier, every financial metric we report will be non-GAAP, with tariff refunds excluded. You'll find the reconciliations in our financial disclosures. At a high level, Q3 revenue and earnings both beat our expectations and our guidance. Rest of world organic revenue was up 5%, operating margin came in at 25%, which is 100 basis points better than guidance, and diluted EPS was $1.44, up 7% year-over-year. Now to the details. Illumina's third quarter revenue was $1.17 billion, an increase of 4.7% year-over-year on a rest of world organic basis, and currency plus acquired revenue contributed just under three percentage points combined to reported growth. Sequencing consumables revenue was $792 million, up 6% year-over-year and up 5% on an organic rest of world basis. High throughput volume accounted for most of the revenue growth, driven by the continuing expansion of the NovaSeq X install base and clinical customers bringing their instruments online. Clinical market sales rose 14% on a rest of world basis, and we still expect mid-teens growth for clinical consumables in 2026. Sequencing consumable sales in research and applied markets fell 6% for rest of world. So far this year, trends have been consistent with the outlook we had entering the year. Revenue has risen sequentially in each of the last two quarters, and we are seeing signs that research activity is stabilizing. We still expect mid to high single-digit declines for research and applied consumables in 2026. Turning to the NovaSeq X transition, roughly 84% of high throughput volume and 60% of revenue is now on the X; in research and applied markets, 90% or more of volume has been on the X in each of the last five quarters, which signals that conversion to X is largely done. So we expect minimal transition pricing headwinds from these customers going forward; in clinical, 78% of volume is currently on the X, and the pace of conversion has slowed in recent quarters. This is the dynamic you have heard us discuss. Some clinical customers are keeping current on-market assays on the 6K while adding X capacity for new tests. We anticipate clinical conversion reaching 80% to 85% in the coming quarters, and as such, we expect the year-over-year pricing headwinds from the X transition to be lower in 2027 than in 2026. With X conversion nearly complete, we believe these charts are becoming less relevant for showing the price and volume dynamics affecting our revenue growth. So we plan to stop showing this slide in our quarterly earnings presentations after Q4 2026. On sequencing activity, gigabase output growth on our connected high and mid-throughput instruments stayed above 30%, which shows that demand remains strong. For Q3, sequencing instruments revenue came in at $106 million, a 2% decline year over year on a rest of world organic basis. We saw higher NovaSeq X placements, but that was offset by softer instrument sales in our Europe, Middle East, Latin America region. X placements rose year over year in both clinical and research markets. Over 90% of our X placements are still instrument sales, though we're noticing growing interest in lease-type arrangements among certain research customers. Demand for the NovaSeq X stays elevated, particularly among some of our largest clinical customers, where we booked several multi-unit capacity expansion orders. That speaks to the value our customers place on the Illumina ecosystem today and for years ahead. Sequencing service and other revenue was $158 million, up 8% on a rest of world organic basis. As Jacob noted in his prepared remarks, we're gaining traction in our Billion Cell Atlas program, continuing to deliver data and converting more backlog into revenue. The pipeline and interest in our programs is very strong. Microarrays and other revenue reached $110 million, up 2% on a rest of world organic basis, and included SomaLogic revenue that beat our initial deal model. Turning to the rest of the P&L: gross margin was 69.4%, up 20 basis points year over year. Operating margin for the quarter was 25%, 100 basis points above our guidance, driven by higher revenue and disciplined investments. EPS was $1.44 per diluted share, above the high end of our guidance range and up 7% versus Q3 of last year. Year to date, EPS is up 12% versus 2025. On cash flow and the balance sheet: cash flow from operations was $419 million, and we generated $378 million of free cash flow in the quarter. We repurchased $9 million worth of stock during the quarter, and at quarter end we had roughly $1.8 billion remaining under our current share repurchase authorizations, and we intend to keep repurchasing shares opportunistically. We closed the quarter with approximately $1.34 billion in cash equivalents and short-term investments, $1.79 billion in total debt, and a leverage ratio of about 1.4 times gross debt to last 12 months EBITDA. All in all, it was a great third quarter, letting us raise our full-year guidance and reinforcing our confidence in the progress we're making toward our financial targets. Now to our full-year 2026 guidance, starting with revenue. We're raising revenue guidance by $30 million at the midpoint to $4.64 to 4.66 billion. That reflects our Q3 outperformance and increased expectations for sequencing consumable sales in the fourth quarter; we still expect rest of world organic growth greater than 5%. Product revenue guidance ranges are unchanged, and for 2026 we expect rest of world organic sequencing consumable growth of mid-single digits and low double-digit instrument growth. We now expect operating margins of approximately 23.6%, at the high end of our previous guidance. Given the increased revenue outlook for this year, that translates into diluted EPS guidance of $5.40 to $5.45 — a rise of $0.08 at the midpoint compared with our earlier guidance, and it represents year-over-year growth of 12% to 13%. For the fourth quarter of 2026, we anticipate revenue between $1.22 billion and $1.24 billion, with organic growth in the rest of the world of roughly 4.5%, comparable to Q3. We expect EPS of $1.51 to $1.56 and an operating margin of approximately 25%. This year has brought tremendous progress. Sequencing adoption across a broad range of clinical applications keeps expanding, and our fast-growing NovaSeq X installed base gives us a robust consumables revenue stream for years ahead. Both revenue and customer interest in our Billion Cell Atlas are growing, and we are only at the beginning of the sizable AI-based predictive biology opportunity in front of us. A strong balance sheet and cash flows provide the flexibility to invest in strategic growth areas that complement our innovative tools; we are excited about our long-term outlook; to close, I want to thank the Illumina team for their continued focus and disciplined execution throughout the year. Thank you for joining our call today. I now invite the operator to open the line for Q&A.
Tycho Peterson
analystHey, thanks everyone. I’d like to dig a bit into the clinical consumable figures. First, are there any stocking orders worth mentioning? You obviously had that in the prior quarter; then Q4 implies, I believe, low double-digit clinical growth. Is that the correct starting point as we consider next year?
Jacob Thaysen
executiveThank you, Tycho. Above all, our overall clinical performance keeps pleasing us. For the entire year, we see ourselves in the mid-teens. In Q3 here, things looked quite similar to Q2, with clinical growth of 14% to 15%, and we keep expecting that to carry on. We will serve our customers and go on serving them. Every quarter brings its puts and takes, but we feel good about how Q4 is shaping up as well.
Tycho Peterson
analystOkay. Then obviously-
Ankur Dhingra
executiveHey, Tycho.
Tycho Peterson
analystGo ahead.
Ankur Dhingra
executiveTycho, regarding your Q4 question. Broadly speaking, we're lifting our Q4 consumables guidance. Our expectations are rising there because of the strong placements we keep seeing; on your growth rate question, I'd note that Q4 last year saw an 11% growth rate for sequencing consumables. So we still anticipate fairly solid growth of 5% to 6% overall in Q4 for consumables. That remains a good growth figure on top of one of the more unusual compares across last year. So that's one factor to consider, but our expectations for Q4 are getting better.
Vijay Kumar
analystHello, Jacob and Ankur. I appreciate you taking my question. I suppose it was a two-part one, in a manner of speaking. The jump-off you have for Q4 here, I believe, suggests roughly 6% for the rest of the world. What I'd like to ask is: given that jump-off, what framework should we use for 2027? Do the LRP targets remain in place? Considering how strong instrument placements have been so far, might instruments turn into a headwind next year? And how would you offset that? Thank you.
Jacob Thaysen
executiveVijay, I appreciate that. It's hard to believe you had to reach question number 2 before anyone asked about 2027 here. Let me give you a few points here. Above all, we'll provide a complete guide on our Q4 earnings call, so the specifics will have to wait; we're still in very healthy market conditions, the clinical market in particular is strong, and we expect clinical to serve as a growth driver for the company into the foreseeable future; beyond that, there are now also opportunities in what we're observing with our multi-omics capabilities, particularly as the research market comes back. We're positioned very well to take advantage of that. Beyond that, the AI market—we're only scratching the surface there, but there's no question that a substantial requirement and need exists for large data sets to actually train models. We can discuss that more later as well. That's the broad framing for how we view the future. What I'll leave you with—and how I'm thinking about the coming year—is that across the last quarters in this year, every quarter, we've been growing our consumables above 5%. So we consider that a good starting point here. We also see ourselves, of course, with what we discussed when we put the strategy in place in 2024, beginning to move ourselves into growth, and the primary driver was that we would complete the NovaSeq X transition, and in doing so also lapse the price impact from it; we're definitely at the latter end of that, as Ankur also mentioned in the prepared remarks. What we're seeing with the elevated placements of NovaSeq X is that this will, of course, keep being a driver for growth as well. So that's how we're thinking about it right now. I'll leave you with that.
Doug Schenkel
analystGood afternoon, and thank you for taking my questions. Regarding NovaSeq X demand, you've had several consecutive quarters of strong X placements now, including over 80 this quarter. Do you see any indication that the recent strength reflects demand being pulled forward relative to what you might have anticipated for future periods versus last quarter and this quarter, or is the sustainability of the purchasing cycle still quite strong at present? Following on from that, how would you characterize the demand mix this quarter between capacity expansion tied to clinical volume growth and transitions and replacements? Thank you very much.
Jacob Thaysen
executiveThanks, Doug. First and foremost, I don't believe there was any pull forward. From my perspective, this falls within ordinary business activity. And on the whole, as I noted earlier, the placements completed during the past four quarters leave us quite satisfied—they in fact beat the results from the initial twelve months of X placements following our launch. That tells us a few things. As I said before, it reflects the current market environment and the opportunity, particularly within the clinical space, which looks very healthy. The new assays being introduced require a great deal of sequencing. In my view, what lies ahead hasn't even become visible yet. Much more is on the way. That intensity is only going to keep rising. And I believe demand for the Xes will remain strong as we move forward. Second, as you likely remember, at AGBT we showcased the innovations we're bringing to the X platform. I also believe our customers see this as the platform worth betting on going forward, and considerably more innovation will emerge—in sequencing quality as well as turnaround times and sequencing capacity. Add to that all the multi-omics assays on the way; so we feel good about where we stand and about the future as well.
Puneet Souda
analystYeah. Hi, Jacob. Thanks for the question. I just wanted to get a handle on the dynamics on the sequencing consumables side. Is this a matter of putting a number of instruments into the clinical space and applying them, obviously, in research, which is driving a shift — lower cost per gigabase, elasticity? Is that what's happening here in the quarter? And then, I just want to understand on 2027, is the high single-digit framework still intact? Just want to get your thoughts there. Thank you.
Jacob Thaysen
executiveYeah; so I'm not sure I fully understood the first question about how the dynamic of sequenced consumables plays out. Maybe
Puneet Souda
analystYeah, on the question of whether you're seeing a lower cost per gigabase from the labs that come to you, basically just because you're putting in a new instrument that gives them cheaper sequencing right away in the first six months?
Jacob Thaysen
executiveWell, the way we think about it, obviously, is that when we moved from the 6K to the X, that was a step down in price, obviously, but it also produced substantially more volume, and that volume keeps going; so it's not just a six-month volume gain we're seeing within the logic of a fixed budget, but we actually do see that, especially in the clinical space, that our customers, as we've discussed before, are building bigger assays, also getting better competitive positioning, and it continues to drive growth and the introduction or further advancement, especially in oncology testing; so I think that is playing out and will keep playing out. So we feel good about how our growth is sitting with consumables, and we think that's going to continue. I will say, of course, that like many other companies, if you come to Illumina and you're willing to sign up for large volume, we are of course very willing to also talk about what the right price point is for that. That's a conversation I'd like to have with the customers. If they come with new assays they'd like to put in place that require substantially more sequencing, we are absolutely more than willing to have that conversation and find how both companies can be successful. That works well. From 2027, as we mentioned, all the way back in 2024, our strategy is to walk ourselves into growth. We were predicting mid-single here for 2025, and we still are on track to deliver on the 2027 of high single digit in that range.
Subbu Nambi
analystHi folks, thanks for giving me a chance to ask. I've got a question about consumables. Looking ahead to 2027, there are two things I want to ask. First, is it still your view that new products could add one to two points of growth? Second, given that you'll finish 2026 with an operating margin of 25%, is that the right starting point, considering there's more room for operating improvement and better mix as you get beyond the pricing headwinds? Thank you.
Jacob Thaysen
executiveOkay, Subbu, I'll take the first question, and just as a reminder, we're still very much focused on Illumina operating in Q4, and we want to deliver on Q4 before getting into the details of 2027. That said, I will note that what we discussed in 2024 was that we would add new growth drivers as well, through both the new assays coming out and, obviously, the data continuing to play out well. Over the last 18 months, we've launched a very, very substantial multi-omics portfolio, and with the SomaLogic acquisition as well, we're very well-positioned in that space; it has momentum, obviously starting from a low base, but this will begin to actually show up in our numbers both here in 2026 and particularly in 2027 and beyond. So we feel good about that. I think, on our operating margin, again, if you look back over the last few years, we've increased or improved margins by 400 basis points. We feel really good about what the team has accomplished over the past years; we've faced a lot of headwinds that we didn't anticipate, and I think the team has shown that we can deliver. This year, electronic component pricing, shipping costs, and obviously some tariffs as well have been big headwinds, and we've still been able to deliver margin expansion; so I feel good about where we are, and I think there's more to come in the years ahead, including in 2027.
Luke Sergott
analystGreat. Thanks. Sorry, I had myself muted. I only wanted to ask about the implied growth in the exit rate for clinical sequencing, and how we should think about the timing into next year — you have all the liquid biopsy players showing strong sample growth, and then there is the conversion where a lot of them move over to the X. How does that unfold with the initial reason concordance studies, and then when does it start flipping back onto the X?
Jacob Thaysen
executiveWell, I think it is unfolding the way we expected. What has pleased us a great deal across the last four quarters is the higher placements of the X. As you know, we operate on a razor blade model as a company, so the more instruments you place — nobody purchases an instrument to park in the corner. Everyone installs one to bring in more revenue. So clearly, each time you place an X, that generates revenue for years ahead. With that, and with the higher placement, we feel good about the growth opportunity in consumables as well for years ahead. As I said earlier, the clinical market is quite healthy. I know many of you want to sit down and debate whether we grow 14%, 15%, or 16% in clinical. The takeaway is that this is a strong market. There is still plenty of application just now coming online; we feel good about that, and we see that it has legs. If you simply look at it, a great point here is the USCAN business, which has kept growing very strongly across the last four quarters in clinical, and we do not think that will stop.
Ankur Dhingra
executiveRight, that’s thoroughly addressed when it comes to clinical growth. Luke, regarding what you said about the clinical side, the one thing I’d tack on is this: keep watching how many tests have hit the market lately, how much volume those on-market tests are growing, and how many clinical trials are still slated to report results within the coming 12 months—which tells you about the new tests headed to market. And that pipeline is really rich.
Dan Arias
analystYeah. Hi, guys. Thanks for the question here.
Jacob Thaysen
executiveDan, please continue.
Dan Arias
analystJacob. Yes. Are you able to hear me?
Ankur Dhingra
executiveYes, please go ahead.
Dan Arias
analystAll right, thank you. Jacob, as you all work to capture this training model, virtual cell, and AI opportunity, could you discuss how you expect genome pricing to factor into that? Clearly, you believe the X is the platform worth backing, yet there are some rather inexpensive genomes being discussed in the market, dropping as low as $50. So how much do you think you may need to reconsider the price elasticity conversation so that you can truly secure those large projects? Is it possible to succeed with the pricing approach you have now, or do you believe it requires whatever the new 35B flow cell could deliver regarding genome cost?
Jacob Thaysen
executiveOkay, so first off, we're feeling genuinely good about exactly where we stand. In my view, AI models go far past what whole genome pricing involves. A great deal feeds into this, so allow me to put it in some context. Above all, I believe we're looking at a major opportunity in what I'd describe as predictability. But should you choose to move into that new logic or world, that could carry a considerable effect on all that we do, both within our own space, and if you consider life science overall, this might transform how we understand biology, and it could certainly also bring major disruption across the entire healthcare industry, where Illumina sits in a very strong position, since what matters here isn't merely the cost of sequencing. What matters is the capacity to build and generate large data sets spanning the genome, the transcriptome, the methylome, and naturally the proteome too. Put those together, and view them from bulk through to single cell as well as in a spatial context. No other firm in this industry holds the broad portfolio and likewise possesses the capacity to generate such data sets; we began with the Billion Cell Atlas. That's a terrific illustration of a functional data set that doesn't just examine something at a point in time, but instead lets you observe what happens to a cell when you alter an up or down-regulated gene. So I think those are the kinds of data sets you should be seeking; thus we feel good about where we stand. Look, Illumina has spent many years in this world handling elasticity. Elasticity is something we love. Whatever opportunity we need to address, we can. And we believe this market might be far, far larger. We possess both the capabilities and the innovation pipeline to be a very strong player in it. So we're developing the datasets ourselves, and we're also examining a flywheel whereby, together with our customers, we create datasets, our customers can extend those datasets, and we can build ever-larger datasets for training those models; so that excites us, and I'm not overly worried about what others are doing at present.
David Westenberg
analystHey there. Thanks, guys. Sorry to keep hammering away at that same clinical sequencing topic, but I think all of us are basically circling the same point. Clinical accounts for 70% of consumables, and how quickly can that expand to land you in that long-term, high single digit growth range? When we look at Signatera, Shield, and so on, we'd like to understand, even through the X transition, what sort of pricing — discounts, or what growth you can capture from those customers on a net basis after that discount as we move into the 2027s, 2028s, 2029s? Because we realize you're kind of pinned to this X, but we also want to know, when we look at that 25%, 30% volume growth kind of rate there, how much can Illumina keep growing? Because we're confident you'll get to participate; we just want to understand the magnitude of that participation. Thank you.
Jacob Thaysen
executiveNo, thanks, Dave. That's quite specific about where we could go on pricing. What I'd leave you with is this: as I said earlier, we collaborate very closely with our customers. I think a lot of our customers are seeing, of course, chances to build larger assays that move into therapy selection, MRD, and also, of course, now with MSK coming alive. So what we're seeing is that obviously we'll keep having those conversations. We'll keep making sure that both sides can grow in alignment with our customers. There may always be some certain gap between the various growth rates, but what we're taking away is that when our customers grow, we also grow very healthily. So we believe there are more opportunities in that space. We think there are more growth opportunities for Illumina. I think we've proven over the last few quarters or few years that we can step back into growth. The conversation 18 months ago was very, very different. I think all of you were questioning whether we could grow at all. Now we sit with a mid-single growth in consumables; now you're questioning how much we can take that. I think you should see that we have a track record showing that we can keep expanding our growth rate in those ranges for consumables.
Ankur Dhingra
executiveYeah, one more point I'd throw in there: during the last quarter, we included the total consumables growth rate for USCAN, which serves as a proxy for some of those customers you're referring to; and inside our U.S. business, the growth rate in that clinical segment sits well above the 14% you mentioned. So we're pretty well indexed in that respect. And keep in mind, the large customers account for a meaningful portion of our business, but Illumina's business is worldwide, and it also gains in other ways from clinical activity around the globe. Inside our U.S. business, that clinical growth rate is well above that 14%.
Kyle Mikson
analystThanks, guys. Sorry about what happened earlier. Congratulations on the quarter. I want to ask about 2027 in a different way. Congrats, I suppose, on delivering on the strategy day from 2024, those numbers, the framework, all of it. I mean, is there upside to that high single digit growth as we go forward? Obviously, as was mentioned earlier, you've got AI, multi-omics, maybe a research inflection, clinical. That feels like it could be longer term too. Could you get to double-digit growth, perhaps while pushing operating margins up into the high 20s? What would that really take?
Jacob Thaysen
executiveYeah, look, Kyle, I'd say this is absolutely not impossible. There is definitely upside to high single digit growth. Keep a few things in mind. When we laid out our strategy in 2024, we were in a negative growth arena, and now we've stepped ourselves into mid-single digit growth. I think we also want to show we can do high single digit before going beyond that. You can also see that over the last few years, this industry and Illumina specifically have had to deal with a lot of headwinds. Pick whichever one you want to talk about, but there have been plenty; so we believe we're operating in a significant market opportunity space, particularly in clinical, and we think that will keep expanding over the years. We're very well positioned, as the research segment comes back, with our multi-omics portfolio, where we see a lot of grants moving in that direction right now; then, of course, the whole AI space, where substantive data sets will be generated and looked for. I think that's something that, with our Billion Cell Atlas, shows we're very well committed. In that space, it's not about just selling sequences anymore. Our customers, and the broad spectrum of customers, are looking for companies like Illumina that can actually generate those data sets. They're much more interested in what those data sets can generate, and obviously the models, how they can perform, rather than the sequencing itself. So we're very well positioned, and there are certainly opportunities to grow beyond that.
Dan Leonard
analystThanks a lot. Jacob and Ankur, both of you spoke quite a bit about BioInsight. At what point will BioInsight show up more clearly in the P&L? Could that happen as early as next year, or is it something further off?
Jacob Thaysen
executiveYeah. Well, first of all, I think we actually set up BioInsight roughly a year ago, and that was the merger of our software piece, which by the way is performing very strongly too. For those of you who came by our booth and attended our symposiums at ASHG, we really showed how crucial software is to the ecosystem; so we're very excited about that. But we merged that with the data, since there are plenty of synergies between the two. You need to produce the data, but you also need to build models on top of it. As we said in 2024, the data and naturally the multi-omics business would begin contributing 1%-2% in the latter portion. So here in 2027 of our strategic period, when we look toward 2024, and that is unfolding quite well. But I think based on how that AI opportunity develops, which in fact appears very promising, it could be considerably larger. But perhaps, Ankur, you'd like to add something on that too.
Ankur Dhingra
executiveSo our current expectation is that at some point during 2027, we ought to have some sort of color we can start to add. The Billion Cell Atlas — and then the second gen, which we've discussed expanding to 5 billion cells — would definitely be among the first drivers in that. Jacob mentioned that we actually have a very broad spectrum of customers in discussion about the Cell Atlas and several other new bio-AI based applications that they're working on. But we anticipate that at some point in 2027, it does become more visible. And the whole point around the new products and BioInsight adding one to two points of growth for 2027 would certainly be an area.
Casey Woodring
analystGreat. Thanks for fielding my questions. I suppose I have two quick clarifications regarding 4Q. Could you put a number on what that additional selling week adds as a tail into the quarter? Do you anticipate any budget flush? That's part one. There's been chatter this week about U.S. trade curbs affecting a few of your Chinese rivals. At the same time, you're still working through the Unreliable Entity List issue with China. I'm just wondering, has anything shifted in how you stand with the Chinese authorities? Now that you've gone back to year-on-year growth in the region in 3Q, what's your read on the ground regarding customer comfort amid geopolitical worries? Thank you.
Jacob Thaysen
executiveYeah. Thanks, Casey. First and foremost, we're obviously quite happy to be growing again in China. Throughout this whole period, our focus has been on collaborating closely with our Chinese customer, continuing to push innovation, and clearly also engaging with regulators in country so that we have a path forward; we feel good; we remain strongly committed to China and to serving our customers. We think there's an enormous opportunity there; we found out about this situation just like many of you did yesterday morning, and naturally, we're working to better grasp what the impact will be. That's the extent of what I know right now. On the budget flush question, we aren't expecting any particular budget flush beyond what's typical for Q4. Ankur, perhaps you can address that.
Ankur Dhingra
executiveOkay, I’ll take that Q4 question, Casey. Jacob already addressed the budget flush piece, so nothing meaningful has been assumed on that front. Should a stronger budget flush materialize, that could represent potential upside for Q4. As for your question on the extra week, let me put that in context. For everyone listening, Illumina typically reports on a fixed number of weeks per quarter, which means that once every 4 years, we wind up with an additional week to finish the cycle and return to a consistent 13-week cycle. That extra week in Q4 has been included in our guidance all year long. The additional week lands during the holidays, in the very early part of January, so the real revenue impact is quite small. That is not a period when we see a lot of top-line activity. So the revenue impact is fairly minimal. On the expense side, naturally, we carry the people cost for one additional week. Both of those items have been reflected in our guidance and thinking throughout the entire year. To be clear, our increased consumables expectations for Q4 come entirely from the strong placements and customer demand we have observed so far.
Dan Brennan
analystGreat. Thanks. Perhaps just one question about AI. I realize there's already been plenty of discussion on that topic, but looking ahead over the next, let's say, 3-plus years or thereabouts, does the bigger opportunity lie on the services side for Illumina via BioInsight, or will it be substantial — or an opportunity — in putting boxes into traditional flow cells? I'm simply curious how that breaks down. Tied to that, regarding the Billion Cell Atlas: based on what you're seeing in your pipeline and backlog, should we think of it right now as leaning more toward single-cell and multi-omics rather than traditional whole genome? And then a quick follow-up about NovaSeq X pricing during the quarter — any color you could offer there would be helpful. Thanks.
Jacob Thaysen
executiveOkay. Good question, Dan. Regarding how we view the AI opportunity, as I said, the industry at present is searching for a really massive data set that's both reproducible and standardized. The trouble is that when you've got individual PIs, or individual postdocs, or others sitting around building small data sets, those tend to be quite noisy, and it's very hard for models to train well on them; we've observed many times that such models do better at predicting where the data originates than at predicting the biology — which is what the experiments were really telling you; that's the reason we see big demand, and a big ask from customers who'd like our help generating large data sets that can support building those models. Since when we produce those large data sets, obviously, we also devote time to making sure they're reproducible, standardized, and so forth. I believe there's big demand for that. There's certainly a huge opportunity for Illumina in what you might call a service business format. At the same time, we are, of course, in the business of placing instruments. You could imagine plenty of customers saying, "We can get access to the Illumina data sets. Can we augment that with our own data that we might want to keep to ourselves for various reasons?" I think we'll see a lot of demand for that too. It will be a blend, but compared with how we traditionally think about it, we also believe there are big service opportunities. This plays extremely well to what Illumina, where we're sitting today. The capabilities we've built up over the last few years in this space are probably not fully understood, but we have truly become experts in how to think about — or how to do — perturbation for different cell lines and what it takes to build that quality. That's what some of our customers are really seeing a lot of benefits in.
Ankur Dhingra
executiveSure, I’ll add a few more points about BCA and how to think about it. Jacob went into it in a lot of detail. What makes our portfolio powerful, since we have a substantial portion of the multi-omic workflows, is that the path we’re on today looks like a mix of whole genome plus proteomics, a mix of single-cell plus transcriptomics, and a mix of spatial plus transcriptomics. Each of those pairings depends either on the specific organs where the research is being done or on the specific disease pathways where the research is taking place; that blend of different multi-omics will differ, but that’s what various kinds of data sets could look like. As we’ve mentioned, our Billion Cell Atlas is a starting point, and it’s already helping demonstrate causality in many areas; however, we do see a route toward multiple combinations, as I was describing, of extra data sets that can be quite meaningful and powerful going forward.
David Westenberg
analystOh, whoops. I didn't even realize I would be coming back on. Perhaps I'll just ask something quick.
Jacob Thaysen
executiveOkay
David Westenberg
analystAbout China — did I get that right? There was growth this quarter: one figure came in at 7% reported and the other at 7% organic, plus double digits. What happened there, I suppose? And then second, how should we think about China going forward? Obviously the Unreliable Entity List came up, but we also didn't exactly expect that. Again, I apologize for that. It's a bad question. I didn't even know I'd be back on. Thank you.
Jacob Thaysen
executiveDave, we always enjoy hearing from you, so thanks for the follow-up question. As I said earlier, I think the way to think about China is that we believe we have been — I think we have shown commitment, demonstrated that we are committed to finding a path forward in China. I think we have good relationships there. First and foremost, we're focusing on what we can control. What we can control is continuing to support our customers, continuing to drive innovations; we see a lot of interest in a lot of our innovations in China, and we believe the opportunity in China is big. I think Chinese customers want to see Illumina playing in the market space, and we will continue to do our best to have a future in China.
Tycho Peterson
analystHey, thanks for taking the follow-up. Ankur, you brought up operating leases — more of them. I get that this was in the context of the research market, but could you maybe say a bit more about that, and is there any chance it carries over into clinical?
Ankur Dhingra
executiveSure, thanks for that question, Tycho. We've been offering both full operating leases and reagent rental models for quite a while now. Demand for them has been rising, among research customers and clinical customers alike. We haven't really seen much of that among our biggest clinical customers, since they've been heavily expanding capacity. However, with mid-sized clinical labs worldwide, including in the U.S. and in Europe, that's where we've noticed an interesting uptick in demand. Still, that offering is open to all of our customers globally.
Tycho Peterson
analystThanks.
Conor McNamara
executiveWe appreciate your being with us today. A recording of today's call can be found in the investor portion of our site. That brings our call to a close, and we hope to see you at events in the weeks ahead.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 131,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Illumina, Inc. earnings transcripts and 131,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.